Publications
Detailed Information
Influence of IGFBP3 Gene Polymorphisms on IGFBP3 Serum Levels and the Risk of Prostate Cancer in Low-risk Korean Men
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Kwanjin | - |
dc.contributor.author | Kim, Jeong H. | - |
dc.contributor.author | Jeon, Hwang G. | - |
dc.contributor.author | Byun, Seok S. | - |
dc.contributor.author | Lee, Eunsik | - |
dc.date.accessioned | 2012-06-14T06:48:32Z | - |
dc.date.available | 2012-06-14T06:48:32Z | - |
dc.date.issued | 2010-06 | - |
dc.identifier.citation | UROLOGY; Vol.75 6;1516.e1–1516.e7 | ko_KR |
dc.identifier.issn | 0090-4295 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77077 | - |
dc.description.abstract | OBJECTIVES To understand the relationship between the -202 A/C single-nucleotide polymorphism (SNP) of the insulin-like growth factor-binding protein 3 (IGFBP3) gene, IGFBP3 serum levels, and risk of prostate cancer (PCa) in a Korean population, as a potential reason for the lower incidence of PCa in the Korean population. METHODS The IGFBP3 levels were measured and the -202 A/C SNP of the IGFBP3 gene was typed for 225 PCa cases and the same number of matched controls. Linear regression analysis and unconditional logistic regression analysis were used to test for the associations between the genotypes and the circulating IGFBP3 levels and the risk of PCa, respectively. To adjust for the potential bias introduced by the hospital cohort, the result of the genotyping was compared with that of 683 community-indwelling healthy men. RESULTS Significantly lower plasma levels of IGFBP3 were noted in the PCa cases. Lower IGFBP3 plasma levels were associated with an increased number of C alleles (P < .001). Compared with the PCa cases, a lower frequency of the C allele was found in the hospital and community controls (P < .05). Compared with AA genotype, logistic regression analysis revealed an increased risk of PCa in subjects who were CC genotype (odds ratio: 2.39, 95% confidence interval: 1.05-5.48). Larger odds (odds ratio: 3.37, 95% confidence interval: 1.35-8.43) for PCa were associated with CC genotype when the analysis was confined to those who had high-risk PCa. CONCLUSIONS The results supported the protective role of -202 A/C SNP of the IGFBP3 gene against PCa in Korean men. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | ELSEVIER SCIENCE INC | ko_KR |
dc.title | Influence of IGFBP3 Gene Polymorphisms on IGFBP3 Serum Levels and the Risk of Prostate Cancer in Low-risk Korean Men | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 박관진 | - |
dc.contributor.AlternativeAuthor | 이은식 | - |
dc.identifier.doi | 10.1016/j.urology.2009.08.023 | - |
dc.citation.journaltitle | UROLOGY | - |
dc.description.citedreference | Raimondi S, 2009, CARCINOGENESIS, V30, P1170, DOI 10.1093/carcin/bgp103 | - |
dc.description.citedreference | Hernandez W, 2007, CARCINOGENESIS, V28, P2154, DOI 10.1093/carcin/bgm190 | - |
dc.description.citedreference | Liu B, 2007, ONCOGENE, V26, P1811, DOI 10.1038/sj.onc.1209977 | - |
dc.description.citedreference | LEE J, 2007, CANC CONTROL, V14, P78 | - |
dc.description.citedreference | Qin LQ, 2007, ASIA PAC J CLIN NUTR, V16, P467 | - |
dc.description.citedreference | Chen C, 2006, CANCER EPIDEM BIOMAR, V15, P2461, DOI 10.1158/1055-9965.EPI-06-0541 | - |
dc.description.citedreference | Severi G, 2006, CANCER EPIDEM BIOMAR, V15, P1137, DOI 10.1158/1055-9965.EPI-05-0823 | - |
dc.description.citedreference | Silha JV, 2006, ENDOCRINOLOGY, V147, P2112, DOI 10.1210/en.2005-1270 | - |
dc.description.citedreference | Moon JW, 2006, INT J CANCER, V118, P353, DOI 10.1002/ijc.21339 | - |
dc.description.citedreference | Li L, 2005, CANCER EPIDEM BIOMAR, V14, P2462, DOI 10.1158/1055-9965.EPI-05-0531 | - |
dc.description.citedreference | Schildkraut JM, 2005, CANCER EPIDEM BIOMAR, V14, P403 | - |
dc.description.citedreference | Chen C, 2005, CANCER, V103, P76, DOI 10.1002/cncr.20727 | - |
dc.description.citedreference | DeLellis K, 2004, CANCER EPIDEM BIOMAR, V13, P1444 | - |
dc.description.citedreference | Peng LH, 2004, MOL ENDOCRINOL, V18, P1109, DOI 10.1210/me.2003-0344 | - |
dc.description.citedreference | Wang LZ, 2003, CANCER RES, V63, P4407 | - |
dc.description.citedreference | Gunnell D, 2003, BRIT J CANCER, V88, P1682, DOI 10.1038/sj.bjc.6600946 | - |
dc.description.citedreference | Chokkalingam AP, 2001, CANCER EPIDEM BIOMAR, V10, P421 | - |
dc.description.citedreference | Deal C, 2001, J CLIN ENDOCR METAB, V86, P1274 | - |
dc.description.citedreference | Verhage BAJ, 2001, UROLOGY, V57, P97 | - |
dc.description.citedreference | BAXTER RC, 2001, MOL PATHOL, V54, P145 | - |
dc.description.citedreference | Stattin P, 2000, J NATL CANCER I, V92, P1910 | - |
dc.description.citedreference | Harman SM, 2000, J CLIN ENDOCR METAB, V85, P4258 | - |
dc.description.citedreference | Platz EA, 1999, CANCER EPIDEM BIOMAR, V8, P1107 | - |
dc.description.citedreference | Tricoli JV, 1999, UROLOGY, V54, P178 | - |
dc.description.citedreference | Parkin DM, 1999, INT J CANCER, V80, P827 | - |
dc.description.citedreference | STANFORD JL, 1999, NIH PUB | - |
dc.description.citedreference | D`Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969 | - |
dc.description.citedreference | Wolk A, 1998, J NATL CANCER I, V90, P911 | - |
dc.description.citedreference | Schaid DJ, 1998, AM J HUM GENET, V62, P1425 | - |
dc.description.citedreference | Chan JM, 1998, SCIENCE, V279, P563 | - |
dc.description.citedreference | Page WF, 1997, PROSTATE, V33, P240 | - |
dc.description.citedreference | Harrela M, 1996, J CLIN INVEST, V98, P2612 | - |
dc.description.citedreference | KAO PC, 1994, J CLIN ENDOCR METAB, V78, P310 | - |
dc.description.citedreference | SHIMIZU H, 1991, BRIT J CANCER, V63, P963 | - |
dc.description.tc | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.